

Date: 4th August, 2023

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2023

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2023.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

Press Release

Revenue up 18% to Rs. 1486 crores in Q-1 FY24.

Vadodara, August 4th, 2023

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June, 2023.

Financial Highlights

- Net Sales grew 18% to Rs.1486 crores for the quarter.
- Net Profit for the quarter at Rs.121 crores.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities”

Operational Highlights

India Branded Business

- Branded Business up by 9% to Rs. 524 Cr in the quarter.
- Branded Business reflected growth of 11%* better than industry growth of 9%*.
- Specialty therapies recorded growth of 12%* vis a vis industry growth of 7%*.
- Acute therapies recorded growth of 16%* vis a vis Industry growth of 10%*. In Anti Infective, Industry has shown growth of 10%* where as Alembic recorded 19%* growth.
- Animal Health business recorded growth of 11% over PY Q1.

* IQVIA Qtr June '23

International Business

- US Generics up 6% to Rs. 390 crores in the quarter.
- Ex-US International Formulations grew 46% to Rs. 266 Crores in the quarter.
- 5 ANDA approvals received during the quarter; 184 Cumulative ANDA approvals.
- 5 ANDA filings during the quarter; Cumulative ANDA filings at 250.

API Business

- API business grew 31% at Rs. 305 crores in the quarter.
- 131 cumulative DMF Filings.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY24	Q1 FY23	% Change
Formulation			
USA	390	367	6%
Ex- US	266	182	46%
India	524	480	9%
API	305	233	31%
Total	1486	1262	18%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 022- 66953681	Phone: +91 265 – 6637630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in